Rocket Lab (RKLB) is the living definition of a round-trip. The stock traded for about $37 last fall, ran to a 52-week high of $151 as the 2025 space-economy melt-up took the whole sector on a ride, and now sits near $66 — down more than half from that peak. And right on cue, the upgrades have started rolling in: KeyBanc lifted the stock to Overweight in June, Citizens moved it to Buy in April, and AInvest's aggregate signal labels it a Buy. The word floating around is "pounce," as if a 56% drawdown is a discount waiting to be collected.
That is a mood, not a valuation. The person pitching the pounce is looking at how far the stock has fallen since the peak. What the number actually says is that the price is still priced for a future Rocket LabRKLB-- hasn't delivered yet.
Let's give the bull side its due first, because the operating story is genuinely good and it deserves to be stated plainly. Rocket Lab just posted record second-quarter revenue of $234 million, up 62% from a year earlier, and built a record backlog of $2.36 billion — up 137% year over year — with more than 90 launches on the books. It booked over $437 million in new launch contracts in the quarter, and signed a $397 million U.S. Space Force program to build and launch "Flatellite" spacecraft. That is contracted, written-down business, the kind of evidence that separates a real scale-up from a meme. The company guided third-quarter revenue to $250–$265 million, so the trajectory is intact.
Quick Backtesting Tool
Now the math that the "pounce" crowd skips. RKLB's market value is about $39 billion and its enterprise value about $37 billion. Revenue this year is tracking toward roughly $1 billion — the company is doing about $770 million over the trailing twelve months and guided the third quarter well north of $250 million. So the enterprise value is roughly 37 times this year's revenue, or about 48 times trailing revenue. For comparison, to get that enterprise value down to a plain-vanilla 10 times sales, Rocket Lab would need roughly $3.7 billion of revenue — nearly four times what it will do this year. And that math still leaves you with a business that loses money. Adjusted EBITDA was a loss each quarter of 2026, and free cash flow is deeply negative, around negative $370 million over the trailing year.
The part worth staring at is where the cash came from. Rocket Lab ended June with $2.13 billion in cash and equivalents, up from $828.7 million at the end of 2025. That jump looks like a fortress balance sheet. It is not. In the first six months of 2026 the company raised $1.53 billion selling stock through at-the-market offerings. The pile is funded by dilution, not by the business printing money. This is a company buying its own growth by selling its own shares at a stretched multiple — which only works if the shares are worth more later.
And the future the shares are priced for keeps moving further out. Rocket Lab's whole premium rests on Neutron, the medium-lift rocket that is supposed to unlock constellation and national-security work and flip the company toward scale economics. On January 21 the first-stage propellant tank ruptured during a hydrostatic pressure test. The debut slipped from mid-2026 to late 2026, and by August management was acknowledging that a 2027 first flight was increasingly likely. The company's own framing — CEO Peter Beck telling investors to stop watching flight one and start watching flight ten — is honest about the risk, but it is also an admission that the revenue inflection the stock already embeds is years out, not quarters.
None of this makes Rocket Lab a bad business. The backlog is real, the defense pipeline is real, and Electron remains a proven franchise. The mistake is concluding that a stock down 56% from an irrational peak is therefore cheap. The upgrades and the buy labels locate the market's mood; they do not establish value, and an opaque aggregate rating tells you nothing about the price you're paying. This is a watch item, not a pounce. The honest break condition is forward earnings showing up: Neutron flying at cadence, the space-system contracts converting to margin, and that 30-something sales multiple compressing to something a real earnings model can defend. Until then, all the "pounce" talk is you buying the position that someone else already sold at $151.
